文献速递前列腺癌

口服GnRH受体拮抗剂Relugolix作为局部中危前列腺癌放疗新辅助/辅助雄激素剥夺治疗的随机对照2期试验

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
PubMed 文献 · Eur Urol · 2020-04-06

这项2期开放标签随机对照试验纳入103例接受根治性外照射放疗和雄激素剥夺治疗的中危前列腺癌患者,比较口服Relugolix与皮下注射Degarelix的疗效与安全性。主要终点显示Relugolix组4-24周内有效去势率(睾酮<1.73nmol/L)为95%,深去势率(<0.7nmol/L)为82%,中位去势时间4天,安全性特征与机制一致。

要点

  • Relugolix在4-24周内有效去势率达95%,中位去势时间4天。
  • 停药3个月后52%患者睾酮恢复,高于Degarelix组的16%。
  • 最常见不良事件为潮热,两组发生率分别为57%和61%。

核心结论

  • Relugolix可在数天内达到去势水平睾酮并在24周内维持,安全性特征与其作用机制一致。

主要发现

  • Relugolix组在1.73nmol/L和0.7nmol/L阈值下的去势率分别为95%和82%,Degarelix组分别为89%和68%。
  • Relugolix组中位去势时间为4天。
  • 两组治疗期间PSA水平和前列腺体积均下降。
  • 停药3个月后,Relugolix组52%患者睾酮恢复,Degarelix组16%恢复(未进行统计学检验)。
  • 停药后生活质量平均分和中位分均改善。

关键数值与推荐

  • 主要终点为Relugolix组治疗4-24周有效去势率(睾酮<1.73nmol/L),结果为95%。
  • 次要终点深去势率(睾酮<0.7nmol/L)在Relugolix组和Degarelix组分别为82%和68%。
  • 最常见不良事件潮热在Relugolix组和Degarelix组发生率分别为57%和61%。
  • 未计划与Degarelix进行正式统计学比较。

临床怎么用

  • 口服每日一次Relugolix可作为注射用雄激素剥夺治疗的新型口服替代选择。
  • Relugolix能快速达到去势水平并维持24周,需关注停药后睾酮恢复情况。

局限性

  • 开放标签设计是潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this clinical setting in comparison with degarelix, an injectable GnRH antagonist. OBJECTIVE: To evaluate the safety and efficacy of relugolix to achieve and maintain castration. DESIGN, SETTING, AND PARTICIPANTS: A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015. INTERVENTION: Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the rate of effective castration (testosterone <1.73nmol/l) in relugolix patients between 4 and 24 wk of treatment. Secondary endpoints included rate of profound castration (testosterone <0.7nmol/l), prostate-specific antigen (PSA) levels, prostate volume, quality of life (QoL) assessed using the Aging Males' Symptoms scale, and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (30-item EORTC core questionnaire [EORTC QLQ-C30] and 25-item EORTC prostate cancer module [EORTC QLQ-PR25]) questionnaires, and safety. No formal statistical comparisons with degarelix were planned. RESULTS AND LIMITATIONS: Castration rates during treatment were 95% and 82% with relugolix and 89% and 68% with degarelix for 1.73 and 0.7nmol/l thresholds, respectively. Median time to castration in the relugolix arm was 4 d. During treatment, PSA levels and prostate volumes were reduced in both groups. Three months after discontinuing treatment, 52% of men on relugolix and 16% on degarelix experienced testosterone recovery (statistical significance of differences not tested). Mean and median QoL scores improved following treatment discontinuation. The most common adverse event was hot flush (relugolix 57%; degarelix 61%). Lack of blinding was a potential limitation. CONCLUSIONS: Relugolix achieved testosterone suppression to castrate levels within days and maintained it over 24 wk with a safety profile consistent with its mechanism of action. PATIENT SUMMARY: Oral once-daily relugolix may be a novel oral alternative to injectable androgen deprivation therapies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. Eur Urol. 2020. PMID: 32273183. doi:10.1016/j.eururo.2020.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。